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ABSTRACT
Objectives To examine the association between migraine
and migraine aura status with risk of haemorrhagic
stroke.
Design Prospective cohort study.
SettingWomen’s Health Study, United States.
Participants 27860 women aged ≥45 who were free from
stroke or other major disease at baseline and had
provided information on self reported migraine, aura
status, and lipid values.
Main outcome measures Time to first haemorrhagic
stroke and subtypes of haemorrhagic stroke.
Results At baseline, 5130 (18%) women reported any
history of migraine; of the 3612 with active migraine
(migraine in the previous year), 1435 (40%) described
having aura. During a mean of 13.6 years of follow-up, 85
haemorrhagic strokes were confirmed after review of
medical records. Compared with women without a history
of migraine, there was no increased risk of haemorrhagic
stroke in those who reported any history of migraine
(adjustedhazard ratio 0.98, 95%confidence interval 0.56
to 1.71, P=0.93). In contrast, riskwas increased in women
with active migraine with aura (2.25, 1.11 to 4.54,
P=0.024). The age adjusted increased risk was stronger
for intracerebral haemorrhage (2.78, 1.09 to 7.07,
P=0.032) and for fatal events (3.56, 1.23 to 10.31,
P=0.02). Four additional haemorrhagic stroke eventswere
attributable to migraine with aura per 10000 women per
year. Women who reported active migraine without aura
had no increased risk for haemorrhagic stroke.
ConclusionMigraine with aura might, in addition to
ischaemic events, also be a risk factor for haemorrhagic
stroke. The relatively low number of events and
attributable risk should caution against definitive
conclusions and call for further confirmation of these
observations.
INTRODUCTION
Migraine is an intermittent often severely disabling
headache disorder that involves the neuronal and vas-
cular systemandhas a prevalence of about 20% inmid-
dle aged women.1-3 Up to a third of affected patients
experience migraine aura, which is characterised by
transient neurological symptoms most often involving
the visual system.
Several hospital andpopulationbased studies4-10 and
meta-analyses11 12 have linked migraine, particularly
migraine with aura, to an increased risk of ischaemic
stroke. Potential explanations for this association
include direct vascular involvement as part of the
migraine pathophysiology,13 genetic poly
morphisms,14 15 and shared risk factors, such as hyper-
tension, smoking, raised cholesterol concentrations,
and use of oral contraceptives.10 12 16 In addition, there
is increasing evidence of pathology of the vessel wall in
migraine, which might also increase the susceptibility
to vascular events, including haemorrhagic stroke.
Specifically, smooth muscle cell dysfunction,17 endo-
thelial dysfunction,18-20 and involvement of genotypes
of the angiotensin converting enzyme15 and the endo-
thelin receptor21 22 have been suggested.
Data on the association between migraine and hae-
morrhagic stroke, however, are sparse,mainly because
of the generally low incidence of haemorrhagic
strokes. Two case-control studies suggested an
association,623 and a large population based study
with health insurance data indicated an association
between peripartum migraine and increased risk of
intracerebral haemorrhage.24
A previous report from the Women’s Health Study
did not find any association between migraine and
increased risk of haemorrhagic stroke.7 After the asso-
ciation betweenmigraine with aura and ischaemic vas-
cular events becamemore apparentwith longer follow-
up,25 26 however, we re-evaluated the association of
migraine and migraine aura status with haemorrhagic
stroke after a mean of over 13 years of follow-up.
METHODS
We analysed data from participants in the Women’s
Health Study, a completed randomised trial designed
to test the benefits and risks of low dose aspirin and
vitamin E in the primary prevention of cardiovascular
disease and cancer among apparently healthy women.
The design, methods, and results have been described
in detail previously.27-29 In brief, a total of 39 876 US
female health professionals aged ≥45 years at baseline
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(1993-6) and without a history of cardiovascular dis-
ease, cancer, or other major illnesses were randomly
assigned to active aspirin (100 mg on alternate days),
active vitaminE (600 IUon alternate days), both active
agents, or both placebos. Baseline information was self
reported and collected by a posted questionnaire that
asked about many cardiovascular risk factors and life-
style variables. Twice in the first year and yearly there-
after participants were sent follow-up questionnaires
asking about study outcomes and other information
during the study period. For the current analysis, we
included follow-up information from the time of ran-
domisation to 2 March 2009.
Before randomisation, blood sampleswere collected
from 28 345 participating women and stored in tubes
containing EDTA. Of these, 27 939 samples could be
assayed for a full lipid profile (Roche Diagnostics,
Basel, Switzerland). We excluded 79 women for
whom we had no information on migraine, leaving
27 860women free from any self reported vascular dis-
ease at baseline.
Assessment of migraine
On the baseline questionnaire, participants were
asked: “Have you ever had migraine headaches?”
and “In the past year, have you had migraine head-
aches?”Wedistinguished betweenwomenwith no his-
tory ofmigraine and those who reported any history of
migraine, active migraine (migraine in the year before
the baseline questionnaire), or previous migraine
(those who reported ever having had a migraine but
none in the year before completing the questionnaire).
Those participants who reported active migraine were
also asked details about their migraine attacks, includ-
ing duration of attack, unilateral location and pulsating
quality of pain, interferencewith daily activities, aggra-
vation by routine physical activity, nausea or vomiting,
and sensitivity to light or sound.Womenwho reported
active migraine were asked whether they had an “aura
or any indication a migraine is coming.” We used
responses to classify affected women into active
migraine with aura and active migraine without aura,
as in other studies.7 25 30
We have previously shown25 that among partici-
pants in the Women’s Health Study who reported
active migraine, over 83% fulfilled all but one of the
first edition International Classification of Headache
Disorders31 criteria (code 1.7, migrainous disorder)
and around 47% fulfilled all criteria (code 1.1 migraine
without aura). We also showed that in a subsample of
women from the Women’s Health Study,32 according
to second edition International Classification of Head-
ache Disorders criteria,33 in the 88% with self reported
active migraine the diagnosis was migraine without
aura (72%) or probable migraine without aura (16%).
Stroke ascertainment
We asked participants who reported a stroke on a fol-
low-up questionnaire for permission to review their
medical records. An endpoints committee of physi-
cians, including a board certified vascular neurologist,
reviewed the medical records to confirm the diagnosis
of stroke. Non-fatal stroke was confirmed if the partici-
pant had a new focal-neurological deficit of sudden or
rapid onset attributable to a cerebrovascular event that
persisted for more than 24 hours. Cases of fatal stroke
were documented by evidence of a cerebrovascular
cause of death obtained from all available sources,
including death certificates and hospital records or
information from next of kin. Clinical information
and results frombrain imagingwereused to distinguish
between major stroke subtypes, with excellent agree-
ment between observers.34 Cases of haemorrhagic
stroke were further subdivided into intracerebral hae-
morrhages and subarachnoid haemorrhages. We did
not include in our analyses instances of ischaemic
stroke with secondary haemorrhagic transformation
into the affected area. The rate of positive imaging
results for the diagnosis of haemorrhagic stroke in the
Women’s Health Study was 97%.35
Statistical analysis
We compared baseline characteristics of participants
according to migraine status.We used analyses of cov-
ariance to adjust continuous measures and direct stan-
dardisation to adjust categorical variables and
incidence rates for haemorrhagic stroke for age.
We used Cox proportional hazard models to calcu-
late age and multivariable adjusted hazard ratios (with
95% confidence intervals) for the association of
migraine and migraine aura status with haemorrhagic
stroke and subtypes of haemorrhagic stroke.We tested
the proportionality assumption of themodel by includ-
ing an interaction term for the categories of migraine
with time and found no significant violation.
As the number of outcome events was relatively low
compared with the number of potential confounders,
we used two approaches for multivariable adjustment.
Firstly,we built amodel that includedonly a limited set
of potential confounders (parsimonious model). This
model included information on age (continuous), his-
tory of hypertension (bloodpressure of at least 140mm
Hg systolic or 90 mm Hg diastolic, or self reported
diagnosis from a physician), smoking (never, past, cur-
rent <15 cigarettes/day, ≥15 cigarettes/day), body
mass index (BMI) (<25, 25-29.9, ≥30), alcohol con-
sumption (rarely/never, 1-3 drinks/month, 1-6
drinks/week, ≥1 drink/day), and total cholesterol con-
centration (quarters of distribution).
Secondly, we used a propensity score36 method to
adjust for confounding. This allowed us to simulta-
neously adjust for a large number of covariates,
which otherwisewould not have beenpossible because
of general modelling constraints.37 38 The propensity
score is the estimated probability of exposure (that is,
migraine status) given a set of covariates (that is, the
potential confounders). We distinguished between a
propensity score for any migraine and a propensity
score for migraine with aura. To estimate the propen-
sity score, we used a logistic regression model that
included age (as before), systolic blood pressure (incre-
ments of 10 mm Hg), antihypertensive treatment,
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smoking (as before), BMI (as before), alcohol con-
sumption (as before), total cholesterol concentration
(as before), exercise (rarely/never, less than once a
week, once to three times a week, four or more times
a week), menopausal status, postmenopausal use of
hormone treatment (never, past, current), history of
use of oral contraceptives, history of diabetes, family
history of myocardial infarction before the age of 60,
annual household income (<$50 000 (£33 000, €40 000
), $50 000-<$100 000, ≥$100 000), highest level of edu-
cation (less than university degree, university degree,
masters degree, or doctorate), use of multivitamins
(never, past, current), ethnicity (white versus other),
interaction terms for age (<55, ≥55) with smoking,
BMI, and oral contraceptive use, and randomised
treatment assignments. Use of other lipid measures
yielded comparable results. We weighted a Cox pro-
portional hazards model based on propensity score
values and used robust estimation of standard errors.
We used standardised mortality ratio weights,39 40
which assign the value 1 for exposed and the propen-
sity score odds for unexposed.
We incorporated an indicator variable for missing
values if the number of women with missing informa-
tion (maximum 1.9% missing) on potential confound-
ing factors was 100 or more (this was the case for BMI
and family history of myocardial infarction before the
age of 60) or otherwise reassigned values of the refer-
ence group or past user group, as applicable.
In exploratory analyses, we evaluated potential
effect modification of the association between
migraine with aura (versus everybody else) and hae-
morrhagic stroke by age (<55, ≥55), history of hyper-
tension (yes, no), smoking status (active, non-active),
total cholesterol concentration (<6.2 mmol/l,
≥6.2 mmol/l), current postmenopausal hormone use
(yes, no), estimated 10 year risk of coronary heart dis-
ease according to Framingham risk score (<5%,
≥5%),41 and randomised assignment to aspirin andvita-
minE.Lastly,we ran aCoxproportional hazardmodel
that adjusted for time varying frequency of non-steroi-
dal anti-inflammatory drug (NSAID) intake and ran-
domised aspirin assignment to explore the role of
these drugs on the association between migraine with
aura and haemorrhagic stroke.
All analyses were performed with SAS (SAS version
9.1, Cary, NC). All tests are two tailed, and we consid-
ered a P<0.05 as significant.
RESULTS
Of the 27 860 participating women, 5130 (18%)
reported any history of migraine, of whom 3612
(70%) reported active migraine (migraine in the year
before thebaselinequestionnaire) and1518 (30%) indi-
cated previous migraine. Of the women with active
migraine, 1435 (40%) were classified as having
migraine with aura. Table 1 summarises the age
adjusted baseline characteristics of participants accord-
ing to migraine and aura status. Compared with
womenwithout a history ofmigraine, those with active
migraine with aura were younger, were less likely to
have a history of diabetes, smoked fewer cigarettes,
and drank less alcohol. Women with migraine with
aura were also more likely to be postmenopausal and
to use postmenopausal hormones.
During a mean of 13.6 years of follow-up (377 711
person years), there were 85 confirmed haemorrhagic
strokes (44 intracerebral haemorrhages, 36 subarach-
noid haemorrhages, and five without a clear distinc-
tion). After adjustment for age, the incidence of
haemorrhagic stroke per 10 000 women per year was
2.3 for those without migraine, 2.5 for those with any
history of migraine, 6.3 for those with active migraine
with aura, 0.8 for those with active migraine without
aura, and 1.3 for those who reported previous
migraine. Compared with women without migraine,
after adjustment for age and an assumption of causal-
ity, there were four additional haemorrhagic stroke
events associated with migraine with aura per 10 000
women per year.
Table 2 summarises the age and multivariable
adjusted hazards ratios for the association between
migraine and risk of haemorrhagic stroke. Compared
with women who did not report history of migraine,
those who reported any history had no increased risk
of haemorrhagic stroke (age adjusted hazard ratio 1.04,
95% confidence interval 0.59 to 1.82, P=0.90). When
we made a distinction with regard to migraine aura,
however, the results differed. After adjustment for
age and compared with women without migraine his-
tory, women with active migraine with aura had
increased risk of haemorrhagic stroke (2.31, 1.15 to
4.64, P=0.019). Adjustment for age, history of hyper-
tension, smoking, BMI, alcohol consumption, and
total cholesterol concentration (parsimonious model)
yielded similar results. Also, adjustment for a large
number of covariates via a regression model weighted
for a propensity score did not substantially attenuate
this finding (2.25, 1.11 to 4.54, P=0.024). Women
who reported active migraine without aura and those
who reported previous migraine had no increased risk
of haemorrhagic stroke.
The figure shows the age adjusted incidence rates for
haemorrhagic stroke for women without a history of
migraine, women with active migraine with aura, and
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those with active migraine without aura. Compared
with women with no history of migraine, the increased
rates of haemorrhagic stroke for women with active
migraine with aura were more apparent towards later
years of follow-up.
To evaluate the association of migraine with aura
with the few subtypes of haemorrhagic stroke (intra-
cerebral haemorrhage n=44; subarachnoid haemor-
rhage n=36) as well as with fatal haemorrhagic stroke
(n=28), we combined women who did not report
migraine, reported migraine without aura, and
reported previous migraine to form a reference
group. The association between active migraine with
aura and haemorrhagic stroke was stronger for intra-
cerebral haemorrhages (hazard ratio adjusted for age
2.78, 1.09 to 7.07, P=0.032) than for subarachnoid hae-
morrhages (1.73, 0.53 to 5.65, P=0.37) and stronger for
fatal (3.56, 1.23 to 10.31, P=0.02) than non-fatal hae-
morrhagic stroke (1.96, 0.78 to 4.93, P=0.15).
With regard to potential effect modification of the
age adjusted association between active migraine with
aura and haemorrhagic stroke, we found stronger
effect estimates for age 55 and above (3.80, 1.61 to
8.97), no history of hypertension (3.23, 1.45 to 7.20),
cholesterol concentrations <6.2 mmol/l (2.86, 1.36 to
6.01), current use of postmenopausal hormones (2.84,
1.19 to 6.76), non-active smokers (2.70, 1.29 to 5.67),
Framingham risk score estimates of coronary heart dis-
ease of <5% (2.98, 1.41 to 6.30), randomisation to vita-
minE (2.87, 1.21 to 6.80), and randomisation to aspirin
placebo (3.27, 1.26 to 8.49).We did not, however, find
any significant effect modification (smallest P value
0.19 for the interaction by age).
Whenwe ran age adjustedCoxproportional hazards
models that controlled for time varying frequency of
NSAID use during the trial period and randomised
aspirin assignment, there was no attenuation in the
hazard ratio for haemorrhagic stroke for women with
migraine with aura (2.34, 1.17 to 4.70).
DISCUSSION
In this prospective study of middle aged and initially
apparently healthy women, we found an association
between migraine with aura and an increased risk of
Table 1 | Age adjusted baseline characteristics according to migraine status in Women’s Health Study (n=27 860). Figures are
percentages of women* unless stated otherwise
Characteristics No migraine history
Active migraine
Previous migraine†With aura Without aura
No of participants 22 730 1435 2177 1518
Mean (SE) age (years) 54.9 (0.05) 53.2 (0.16) 52.6 (0.12) 55.5 (0.19)
Mean (SE) total cholesterol (mmol/l) 5.5 (0.01) 5.5 (0.03) 5.5 (0.02) 5.6 (0.03)
Mean (SE) BMI 25.9 (0.03) 25.8 (0.13) 26.2 (0.11) 26.1 (0.13)
History of hypertension‡ 24.6 25.5 26.0 30.4
Antihypertensive treatment 13.0 13.9 14.3 17.2
History of diabetes 2.5 1.8 1.6 2.7
Smoking:
Never 51.3 52.6 56.3 50.6
Past 37.0 37.3 34.5 35.4
Current <15 cigarettes 4.4 3.9 3.5 5.2
Current ≥15 cigarettes 7.3 6.2 5.8 8.9
Alcohol consumption:
Rarely/never 43.5 48.3 47.4 45.1
1-3 drinks/month 13.1 13.1 15.5 14.2
1-6 drinks/week 32.7 30.3 30.1 30.4
≥1 drink/day 10.8 8.3 7.1 10.3
Physical activity:
Rarely/never 37.0 38.2 39.4 39.1
<1/week 19.2 20.5 21.7 20.1
1-3/week 32.3 30.7 29.2 29.4
≥4/week 11.6 10.6 9.7 11.3
Premenopausal 28.1 23.9 26.2 25.0
Current postmenopausal hormone use 41.7 51.0 46.7 43.7
Family history of myocardial infarction
before age 60
12.6 14.3 13.0 13.8
Use of multivitamins 13.1 13.2 11.2 11.5
Randomised to aspirin 50.2 49.1 50.5 47.8
Randomised to vitamin E 50.1 51.5 48.1 50.0
*Proportions might not add up to 100% because of rounding or missing values.
†History of migraine but no active migraine in year before completion of baseline questionnaire.
‡Systolic blood pressure ≥140 mm Hg, diastolic blood pressure of ≥90 mm Hg, or self reported diagnosis from physician.
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haemorrhagic stroke. Compared with women with no
history of migraine and after adjustment for many
potential confounders through a propensity score
weighting, women who reported active migraine with
aura had over twice the risk of haemorrhagic stroke.
The low number of haemorrhagic strokes and the rela-
tively low attributable risk, however, should caution
against definitive conclusions about the association.
Women who reported active migraine without aura
or migraine in the more distant past had no increased
risk of haemorrhagic stroke.
Our findings extend previous observations from the
Women’s Health Study of an association between
migrainewith aura and increased risk of ischaemic vas-
cular events, including ischaemic stroke, myocardial
infarction, coronary revascularisation, angina, and
death from ischaemic cardiovascular causes.25 The
magnitude and pattern of the association between
migraine with aura and haemorrhagic stroke are simi-
lar to those of migraine with aura and ischaemic vascu-
lar events. In contrast with the association between
migraine with aura and ischaemic stroke, which is
stronger among younger individuals,7 the association
with haemorrhagic stroke seems more apparent in the
older age group. We did not, however, find a signifi-
cant effect modification.
Comparison with other studies
Our data contrast with a previous report from the
Women’s Health Study in which migraine with aura
was not associatedwith increased risk of haemorrhagic
stroke after a mean of nine years of follow-up.7 The
pattern of association suggests that this discrepancy is
caused by the difference in length of follow-up. The
increased risk for haemorrhagic stroke among
women with migraine with aura becomes apparent
only after longer follow-up (mean of 13.6 years in the
present study), similar to a pattern observed for ischae-
mic vascular events.25 26
While several studies4-82342 and twometa-analyses1112
have evaluated the association of migraine, and specifi-
cally migraine with aura, with ischaemic stroke, data on
the association between migraine and haemorrhagic
stroke are sparse. One case-control study found an
increased risk of haemorrhagic stroke for people with a
family history of migraine (odds ratio 2.30, 95% confi-
dence interval 1.35 to 3.90), but in those with active
migraine the increased risk was more apparent for peo-
ple with migraine without aura (1.84, 0.77 to 4.39).6
Another study of 430 women aged 15-44 with stroke
used two control groups (their matched neighbours
and hospital controls) to evaluate the association
between migraine and haemorrhagic stroke.23 Com-
pared with the neighbour control group, women with
migraine who did not use oral contraceptives had an
increased risk of haemorrhagic stroke (1.8, 1.2 to 2.7).
The increased risk was not apparent when the hospital
control group was used as reference, whichmight relate
to biases when using hospital based control populations.
Women with migraine who additionally used oral con-
traceptives had a significantly increased risk of haemor-
rhagic stroke regardless of the control group used for
comparison.23 Information on migraine aura was not
available in this study. In a large population based sam-
ple of inpatients, ICD-9 coding for migraine in the peri-
natal periodwas associatedwith various vascular events,
including intracerebral haemorrhage (9.1, 3.0 to 27.8).24
Potential mechanisms linking migraine with haemorrhagic
stroke
In addition to previous studies that have identified
migraine with aura as a marker of ischaemic vascular
events, our data suggest that it is also a marker of
increased risk of haemorrhagic stroke. Potential
mechanisms by which migraine with aura could be
linked with increased risk of haemorrhagic stroke, how-
ever, are currently speculative. There could be several
potential links. Firstly, one link might involve dysfunc-
tion or pathology of the vessel wall, which is supported
by studies reporting smooth muscle cell dysfunction17
and endothelial dysfunction in migraine1820 as well as
pathological vascular resistance, already apparent in
young people with migraine.19 This could ultimately
increase the risk of intracerebral haemorrhage as well
as the risk of lacunar infarcts.43 Secondly, there might
be a synergistic effect between the vascular dysfunction
inmigraine and additional risk factors for haemorrhagic
stroke. Previous results have suggested that the
Table 2 | Hazard ratios (95% confidence intervals) for haemorrhagic strokes adjusted for age, multivariables, and propensity score according to migraine
status in Women’s Health Study (n=27 860)
No migraine
history
(n=22 730)
Any history of migraine
(n=5130)
Active migraine
Previous migraine*
(n=1518)
With aura
(n=1435)
Without aura
(n=2177)
No with haemorrhagic stroke (n=85) 70 15 9 3 3
Age adjusted 1.00 1.04 (0.59 to 1.82), P=0.90 2.31 (1.15 to 4.64), P=0.019 0.52 (0.16 to 1.66), P=0.27 0.63 (0.20 to 1.99), P=0.43
Multivariable adjusted
(parsimonious) model†
1.00 1.03 (0.59 to 1.81), P=0.91 2.34 (1.16 to 4.70), P=0.017 0.54 (0.17 to 1.72), P=0.29 0.59 (0.19 to 1.88), P=0.37
Propensity score adjusted‡ 1.00 0.98 (0.56 to 1.71), P=0.93 2.25 (1.11 to 4.54), P=0.024 0.49 (0.14 to 1.70), P=0.26 0.45 (0.14 to 1.48), P=0.19
*History of migraine but no active migraine in year before completion of baseline questionnaire.
†Adjusted for age, history of hypertension, smoking, BMI, alcohol consumption, and total cholesterol concentration.
‡One propensity score calculated for overall migraine and one for having migraine with aura. Both models included information on age, systolic blood pressure, use of antihypertensive
medication, smoking, BMI, alcohol consumption, exercise, total cholesterol concentration, postmenopausal status, postmenopausal hormone use, history of oral contraceptive, history of
diabetes, family history of myocardial infarction before age 60, annual household income, level of education, multivitamin use, ethnicity, randomised treatment, and interaction terms for
age with smoking, BMI, and oral contraceptives. Hazard ratios estimated by weighted Cox proportional hazard models.
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association between migraine with aura and ischaemic
stroke is strongest among individuals with a low risk of
vascular events30 as measured by the Framingham risk
score for coronary heart disease, a pattern that is also
suggested for haemorrhagic stroke in our data. Thirdly,
both migraine and intracerebral haemorrhage could be
related to a common cause, such as arteriovenous
malformations,44 but such malformations are only a
rare cause of migraine. Fourthly, migraine has been
linked to platelet dysfunction,45 which could lead to an
increased susceptibility to bleeding. Most studies, how-
ever, point towards an activation of the coagulation
cascade,1846 and there is no evidence of a generalised
increased risk of bleeding among people with migraine.
Finally, use of pain medication that inhibits platelet
aggregation, such as aspirin andNSAIDs, could increase
the risk of haemorrhagic stroke among patients with
migraine. We believe this is an unlikely explanation of
our findings as such medications are used by patients
with migraine both with and without aura; in addition,
the associationbetweenmigrainewith aura andhaemor-
rhagic stroke in our studywas stronger among those ran-
domised to an aspirin placebo. Furthermore, when we
adjusted for time varying NSAID use and randomised
aspirin assignment the results were unchanged.
Strengths and limitations
Our study has several strengths, including its large
sample size, haemorrhagic stroke cases confirmed by
an endpoints committee of physicians with high agree-
ment between raters in the classification of major sub-
types of stroke,34 and homogeneity of the study
participants, which should reduce confounding.
Furthermore, we used a propensity score technique
that allowed us to control for a large number of poten-
tial confounders, including socioeconomic and life-
style factors that might play a role in the occurrence
of haemorrhagic stroke47 48 and that have also been
linked with migraine.49 50
Several limitations should, however, be considered.
Firstly, and most importantly, the number of cases of
haemorrhagic stroke was small (n=85) and only nine
cases occurred among women with active migraine
with aura. Thus, and despite statistical significance,
our data should be interpreted with caution. Secondly,
migraine status was self reported by participants and
not classified according to strict International Head-
ache Society criteria.33 Although previous reports
from the Women’s Health Study have shown good
agreement of migraine classification with modified
International Headache Society criteria,25 26 misclassi-
fication is possible. As our study design is prospective,
however, such misclassification would probably be
random and unlikely to explain the observed associa-
tion between active migraine with aura and haemor-
rhagic stroke and, if present, would probably lead to
an underestimation of the effect. Thirdly, we had no
further details on migraine aura in this cohort, which
would have allowed us to classify participants accord-
ing to International Headache Society criteria for aura
or to take frequency of aura into account. Our preva-
lence of aura, however, is in the range reported in other
population based studies.3 51 Fourthly, the Women’s
Health Studywas designed as a randomised controlled
trial of aspirin and vitamin E, and specifically for
aspirin there is a concern of increased risk of haemor-
rhagic stroke. In theWomen’sHealth Study, however,
neither aspirin nor vitamin E assignment was asso-
ciated with risk of haemorrhagic stroke,28 29 rando-
mised treatment assignments were evenly distributed
across migraine groups, and we found no significant
effect modification of the association between
migrainewith aura andhaemorrhagic stroke according
to randomised treatment assignments. Fifthly, despite
adjustment for many potential confounders through a
propensity score technique, residual and unmeasured
confounding remains possible as our study is observa-
tional. Finally, participants in the Women’s Health
Study were middle aged health professionals, most of
whom were white, and thus generalisability to other
populations of women might be limited.
Clinical implications
Migraine with aura has been consistently linked with
an increased risk of ischaemic stroke andmight also be
a marker of increased risk for other ischaemic events.
Our results extend those previous findings and suggest
that migraine with aura might also be a marker for
increased risk of haemorrhagic stroke. Because of the
relatively low attributable risk (four additional hae-
morrhagic strokes associated with migraine with aura
per 10 000 women per year), however, there are no
immediate implications for clinicians or patients
other than the evaluation of prevalent cardiovascular
risk factors that might influence ischaemic and hae-
morrhagic vascular events.
Unanswered questions and future research
There are many unanswered questions, particularly
involving specifics on migraine aura and biological
mechanisms linking migraine with aura to an increased
risk of haemorrhagic stroke. The low attributable risk
might mean that the increased risk of haemorrhagic
stroke is limited to a subgroup of patients withmigraine
with aura. In addition to studies targeting potential bio-
logical mechanisms, future collaborative efforts are
needed to study whether migraine aura specifics or the
WHAT IS ALREADY KNOWN ON THIS TOPIC
Migraine with aura has been associated with increased risk of ischaemic stroke and other
ischaemic vascular events
Migraine with aura has also been linked to an adverse cardiovascular risk profile and
endothelial dysfunction
WHAT THIS STUDY ADDS
In a large prospective study of female health professionals aged 45 years or older at study
entry, migraine with aura was associated with increased risk of haemorrhagic stroke
Absolute numbers and attributable risk were low, arguing against definitive conclusions, and
calling for further confirmation of these observations
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course of migraine influences risk of subsequent ischae-
mic and haemorrhagic vascular events.
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